Results 1 to 10 of about 45,004 (157)

Nasopharyngeal S. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme [PDF]

, 2018
Background: In Belgium, the infant pneumococcal conjugate vaccine (PCV) programme changed from PCV7 (2007-2011) to PCV13 (2011-2015) and to PCV10 (2015-2016). A 3-year nasopharyngeal carriage study was initiated during the programme switch in 2016.
Blaizot, Stéphanie, Desmet, Stefanie, Goossens, Herman, Malhotra-Kumar, Surbhi, NPcarriage study group, the, Theeten, Heidi, Van Damme, Pierre, Van Heirstraeten, Liesbet, Van Herck, Koen, Verhaegen, Jan, Wouters, Ine   +10 more
core   +2 more sources

Pneumococcal Vaccines

Indian Journal of Medical Microbiology, 2018
Streptococcus pneumoniae continues to take a heavy toll on childhood mortality and morbidity across the developing world. An estimated 10.6 million invasive pneumococcal diseases (IPDs) occur every year, with nearly 1 million deaths in children under 5 years of age. Introduction of vaccines in the childhood immunisation programme in developed world has
Anand, Manoharan, Ranjith, Jayaraman
openaire   +2 more sources

From the microbiome to the central nervous system, an update on the epidemiology and pathogenesis of bacterial meningitis in childhood [version 1; referees: 3 approved] [PDF]

, 2017
In the past century, advances in antibiotics and vaccination have dramatically altered the incidence and clinical outcomes of bacterial meningitis. We review the shifting epidemiology of meningitis in children, including after the implementation of ...
Janowski, Andrew B, Newland, Jason G
core   +3 more sources

Challenges to estimating vaccine impact using hospitalization data. [PDF]

, 2017
Because the real-world impact of new vaccines cannot be known before they are implemented in national programs, post-implementation studies at the population level are critical.
Bruhn, Christian AW, Kürüm, Esra, Lustig, Roger, Schuck-Paim, Cynthia, Simonsen, Lone, Taylor, Robert J, Weinberger, Daniel M   +6 more
core   +3 more sources

Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. [PDF]

, 2008
BACKGROUND: Streptococcus pneumoniae serotype 1 causes > 20% of invasive disease, among all age groups combined, in The Gambia. In contrast, it is rarely detected in carriage studies. This study compares the molecular epidemiology of S.
Adegbola, Richard A, Akisanya, Abiodun, Antonio, Martin, Awine, Timothy, Corrah, Tumani, Cutts, Felicity, Egere, Uzochukwu, Enwere, Godwin, Greenwood, Brian M, Hakeem, Ishrat, Hill, Philip C, Lahai, George, Nsekpong, David, Sankareh, Kawsu, Secka, Ousman, Zaman, Syed MA   +15 more
core   +2 more sources

The new pneumococcal vaccine [PDF]

Clinical Microbiology and Infection, 2002
Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years.
openaire   +3 more sources

IL-17 can be protective or deleterious in murine pneumococcal pneumonia [PDF]

, 2018
Streptococcus pneumoniae is the major bacterial cause of community-acquired pneumonia, and the leading agent of childhood pneumonia deaths worldwide. Nasal colonization is an essential step prior to infection.
Bayes, Hannah K., Evans, Tom J., Mitchell, Tim J., Ritchie, Neil D., Ritchie, Ryan   +4 more
core   +3 more sources

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Pneumococcal vaccine for asthma

Cochrane Database of Systematic Reviews, 2002
Infection with Streptococcus pneumoniae is an important cause of pneumonia and other serious illnesses, particularly amongst those with certain high-risk medical conditions such as asthma. Although pneumococcal vaccine is routinely advocated for people with asthma, there is uncertainty about the evidence base that underpins this recommendation.To ...
Aziz Sheikh, Sangeeta Dhami, Bernadette Alves   +2 more
openaire   +5 more sources

Populations Addressed in Vaccines Approved via the European Medicines Agency

Clinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf, Lukas Westphal, Jonathan Kimmelman, Christine E. Hallgreen   +3 more
wiley   +1 more source